CRISPR Therapeutics - CRSP Stock Forecast, Price & News

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last year. There are currently 1 sell rating, 8 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CRSP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRSP, but not buy additional shares or sell existing shares.
View CRSP analyst ratings or view top-rated stocks.

18 equities research analysts have issued 1 year price targets for CRISPR Therapeutics' stock. Their CRSP share price forecasts range from $39.00 to $123.00. On average, they predict the company's share price to reach $72.89 in the next twelve months. This suggests a possible upside of 67.8% from the stock's current price.
View analysts price targets for CRSP or view top-rated stocks among Wall Street analysts.

CRISPR Therapeutics' stock was trading at $40.65 at the start of the year. Since then, CRSP shares have increased by 6.8% and is now trading at $43.43.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our CRSP earnings forecast.

CRISPR Therapeutics AG (NASDAQ:CRSP) issued its earnings results on Tuesday, February, 21st. The company reported ($1.41) earnings per share for the quarter, topping the consensus estimate of ($2.27) by $0.86. The firm earned $6 million during the quarter, compared to analysts' expectations of $7.37 million. CRISPR Therapeutics had a negative trailing twelve-month return on equity of 31.85% and a negative net margin of 54,271.70%. CRISPR Therapeutics's quarterly revenue was down 53.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.84) EPS.

ETFs with the largest weight of CRISPR Therapeutics (NASDAQ:CRSP) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), ARK Genomic Revolution ETF (ARKG), Loncar Cancer Immunotherapy ETF (CNCR), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA), ARK Innovation ETF (ARKK), AXS Green Alpha ETF (NXTE) and Jacob Forward ETF (JFWD).

Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Block (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP).

(CRSP) raised $75 million in an initial public offering (IPO) on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager.

CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

CRISPR Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (10.00%), Sumitomo Mitsui Trust Holdings Inc. (5.12%), Nikko Asset Management Americas Inc. (5.12%), T. Rowe Price Investment Management Inc. (3.82%), NEA Management Company LLC (2.03%) and Price T Rowe Associates Inc. MD (1.43%). Insiders that own company stock include Bradley J Phd Bolzon, Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Rodger Novak, Samarth Kulkarni, Tony W Ho and Tony W Ho.
View institutional ownership trends.

Shares of CRSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRSP stock can currently be purchased for approximately $43.43.

CRISPR Therapeutics (NASDAQ:CRSP) has a market capitalization of $3.42 billion and generates $1.20 million in revenue each year. The company earns $-650,170,000.00 in net income (profit) each year or ($8.37) on an earnings per share basis.

The company employs 473 workers across the globe.

CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The official website for the company is www.crisprtx.com. The company can be reached via phone at (141) 561-3277 or via email at susan.kim@crisprtx.com.